Ridaforolimus (Deforolimus AP23573) BEZ235 SF1126 XL418 XL765 XL147 Everolimus (RAD001) PX-866 XL281 Perifosine XL228 RDEA119 GDC-0941 bismesylate PF-04691502 GDC-0973 Sirolimus (Rapamune) GDC-0980 Temsirolimus (Torisel, CCI-779) Selumetinib (AZD6244)

PF-04691502

This drug under development by Pfizer Oncology is in a Phase I trial.

Mode of action:  this drug targets the PI3K / mTOR pathway.

Manufacturer:  under development by Pfizer Oncology
 

Current Clinical Trials relevant to GIST:

NCT00927823: A Trial To Assess Safety And Tolerability Of  PF-04691502 In Cancer Patients